The role of chemoprevention by selective cyclooxygenase-2 inhibitors in colorectal cancer patients - a population-based study

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Yang, Yi Hsin ^a,b   Yang, Yea Huei K ^c   Cheng, Ching Lan ^c   Ho, Pei Shan ^a,b   Ko, Ying Chin ^a,d,e  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Chemoprevention; Colorectal cancer; Population based study; Selective COX 2 inhibitor

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ROFECOXIB;

ADULT; AGED; ARTICLE; CANCER RISK; CHEMOPROPHYLAXIS; COLORECTAL CANCER; COMORBIDITY; CONTROLLED STUDY; DRUG SELECTIVITY; DRUG TARGETING; ENZYME INHIBITION; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; RISK REDUCTION; TAIWAN; TREATMENT DURATION; TREND STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHEMOPREVENTION; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; RISK; TAIWAN; YOUNG ADULT;

EID: 84870442656     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-582     Document Type: Article

References (19)

1. Moreira L, Castells A. Cyclooxygenase as a target for colorectal cancer chemoprevention. Curr Drug Targets 2011, 12(13):1888-1894. 10.2174/138945011798184218, 21158711.
2. Cancer registry annual report 2008 2011, Taiwan: R.O.C.
3. Lanas A, Ferrandez A. NSAIDs and the colon. Curr Opin Gastroenterol 2009, 25(1):44-49. 10.1097/MOG.0b013e3283157c4d, 19114773.
4. Sarkar FH, Adsule S, Li Y, Padhye S. Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy. Mini Rev Med Chem 2007, 7(6):599-608. 10.2174/138955707780859431, 17584158.
5. Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 2005, 23(12):2840-2855.
6. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007, 115(12):1634-1642. 10.1161/CIRCULATIONAHA.106.181424, 17325246.
7. Cooper K, Squires H, Carroll C, Papaioannou D, Booth A, Logan RF, Maguire C, Hind D, Tappenden P. Chemoprevention of colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2010, 14(32):1-206.
8. Ray WA, MacDonald TM, Solomon DH, Graham DJ, Avorn J. COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease. Pharmacoepidemiol Drug Saf 2003, 12(1):67-70. 10.1002/pds.798, 12616850.
9. WHO Collaborating Centre for Drug Statistics Methodology, ATC/DDD Index 2012, Oslo, Norway: World Health Organization, http://www.whocc.no/atc_ddd_index.
10. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992, 45(6):613-619. 10.1016/0895-4356(92)90133-8, 1607900.
11. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005, 43(11):1130-1139. 10.1097/01.mlr.0000182534.19832.83, 16224307.
12. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006, 355(9):873-884. 10.1056/NEJMoa061355, 16943400.
13. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006, 355(9):885-895. 10.1056/NEJMoa061652, 16943401.
14. Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, Lanas A, Bolognese JA, Oxenius B, Horgan K, Loftus S, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006, 131(6):1674-1682. 10.1053/j.gastro.2006.08.079, 17087947.
15. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 2000, 320(7250):1642-1646. 10.1136/bmj.320.7250.1642, 27410, 10856067.
16. Rostom A, Dube C, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 2007, 146(5):376-389.
17. Johns LE, Houlston RS. A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol 2001, 96(10):2992-3003. 10.1111/j.1572-0241.2001.04677.x, 11693338.
18. Carroll C, Cooper K, Papaioannou D, Hind D, Pilgrim H, Tappenden P. Supplemental calcium in the chemoprevention of colorectal cancer: a systematic review and meta-analysis. Clin Ther 2010, 32(5):789-803. 10.1016/j.clinthera.2010.04.024, 20685491.
19. Giovannucci E, Stampfer MJ, Colditz GA, Rimm EB, Trichopoulos D, Rosner BA, Speizer FE, Willett WC. Folate, methionine, and alcohol intake and risk of colorectal adenoma. J Natl Cancer Inst 1993, 85(11):875-884. 10.1093/jnci/85.11.875, 8492316.